芳香化酶抑制剂改善青少年身高的临床应用专家共识

Expert consensus on the clinical application of aromatase inhibitors to improve adolescent height

芳香化酶抑制剂在全球和中国都广泛应用于改善身高,但因属于超适应证用药,且应用时间相对较短,故国内外对用药的适应证、疗效、不良反应缺乏一致的认识和专家共识。因此中国老年保健协会生长发育和性腺疾病分会和中国医师协会青春期医学与健康专业委员会组织国内28位生长发育方面专家,以牛津大学循证医学中心临床证据水平分级和推荐级别为参照,围绕芳香化酶抑制剂治疗儿童矮身材、改善成年终身高的疗效、不良反应、注意事项、使用剂量和用药疗程等问题,筛选出初步推荐意见。再结合德尔菲法评价意见最终确定14条推荐意见,以规范芳香化酶抑制剂改善青少年身高的临床应用。

Aromatase inhibitors have been widely used to improve height in the world and China.However,due to their off-label use and relatively short application time,there is a lack of consistent understanding and expert consensus on the indications,efficacy,and side effects of the drugs at home and abroad.Therefore,the Growth and Development and Gonadal Diseases Committee of Chinese Aging Well Association and the Adolescent Medicine and Health Professional Committee of the Chinese Medical Doctor Association organized 28 domestic experts in growth and development,based on the clinical evidence level classification and recommendation level of the Oxford University Evidence-Based Medicine Center to establish some preliminary recommendations on the efficacy,adverse reactions,precautions,dosage,and course of use of aromatase inhibitors in treating children with short stature and improving their year-end height.Combined with the Delphi method evaluation,14 recommendations were finally formulated to standardized the clinical application of aromatase inhibitors in improving adolescent height.